Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs SAP SE (SAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs SAP SE — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while SAP SE trades at $221.95 (market cap $254.61B). The key difference: SAP SE is far larger — about 260.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and SAP SE pays a 1.33% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and SAP SE for 118 Days on average.
| MRVI | SAP | |
|---|---|---|
Market Cap | $977.37M | $254.61B |
Volume | 2,742,564 | 1,684,839 |
Sector | Health | Technology |
52-Week High | $9.00 | $280.46 |
52-Week Low | $2.83 | $146.38 |
Typical Hold Time | 0 Days | 118 Days |
Enterprise Value | $1.08B | $253.35B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SAP trades at $219.75, up 0.87% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $36.8B in 2025 and a net income margin of 20.41%. Recent earnings show a mix of beats and one miss, while analyst consensus is a Buy with a $253.60 price target. Cloud revenue growth of 24% in Q2 2026 and AI initiatives are key drivers, though competition and margin pressures from cloud transitions pose challenges.
The outlook for SAP is positive, supported by robust cloud adoption and AI integration, offering potential upside to the consensus target. Risks include execution on AI capabilities, competitive threats from new entrants, and macroeconomic sensitivity in software spending. The stock's valuation at a P/E of 29.48 requires sustained earnings growth to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About SAP SE
Founded in 1972 by former IBM employees, SAP provides database technology and enterprise resource planning software to enterprises around the world. Across more than 180 countries, the company serves 440,000 customers, approximately 80% of which are small to medium-size enterprises.
Read more on SAP →
